Pasithea Therapeutics Corp. (KTTA) - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pasithea Therapeutics Corp. on February 20, 2026. The Company is a Delaware corporation with its principal executive offices in Miami Beach, Florida. It is classified as an emerging growth company. The report addresses a regulatory notice regarding the continued listing of its securities on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance issue rather than financial performance results.
Material Changes and Listing Status
On February 20, 2026, the Company received a written notice from Nasdaq indicating non-compliance with the $1.00 minimum bid price requirement (Listing Rule 5550(a)(2)). This non-compliance is based on the closing bid price of the Company's common stock for the 30 consecutive business days prior to the notice. The notice does not result in immediate delisting.
Outlook, Management Commentary, and Risks
- Compliance Period: The Company has been granted an initial 180 calendar days, until August 19, 2026, to regain compliance.
- Path to Compliance: Compliance will be confirmed if the bid price closes at or above $1.00 per share for a minimum of ten consecutive business days during the compliance period.
- Alternative Options: If the Company fails to regain compliance within the initial 180 days, it may be eligible for an additional 180-day period if it meets other listing requirements and notifies Nasdaq of its intention to cure the deficiency, potentially via a reverse stock split.
- Delisting Risk: Failure to regain compliance or cure the deficiency may lead to a delisting determination, which the Company may appeal to a hearings panel.
- Operational Impact: Management states that the receipt of the notice does not affect the Company's business, operations, or SEC reporting requirements.
Key Facts for Investor Verification
- Verify the current trading price of KTTA to assess the likelihood of meeting the $1.00 bid price requirement within the 180-day window.
- Monitor future announcements regarding the potential execution of a reverse stock split if the bid price does not recover naturally.
- Confirm the Company's status regarding other Nasdaq listing requirements (e.g., market value of publicly held shares) which are prerequisites for an extended compliance period.
- Review the Company's cash position in subsequent filings to ensure it has sufficient liquidity to fund operations while addressing the listing deficiency.